Bioenvision to Hold Fiscal 2007 Second Quarter Financial Results Conference Call on Thursday, February 8, 2007

  
    
  
  
    
      Bioenvision Inc. (NasdaqGM:BIVN) will hold a live webcast of its 
      quarterly conference call at 10:00a.m. EST on Thursday, February 8th, 
      2007. Jim Scibetta, Chief Financial Officer, will host the call. Senior 
      management will discuss the Company’s 
      financial results as of December 31, 2006, the progress towards its 
      goals, and additional corporate activities, including the EMeA filing 
      for Evoltra® in 
      adult acute myeloid leukemia (AML). Bioenvision will announce the 
      highlights of these topics in a press release to be issued before the 
      market opens on February 8, 2007, prior to the conference call.
    
    Conference Call Information:

Date: 2/8/07
Time: 10:00a.m. Eastern Standard Time
Toll free (US & Canada): 866-585-6398
International: 416-849-9626
Webcast: www.bioenvision.com

A replay of the call and webcast will be available for 14 days.

Replay number (US & Canada): 866-245-6755
Replay number international: 416-915-1035
Replay passcode: 752762
Webcast replay: www.bioenvision.com
    
      About Bioenvision
    
    
      Bioenvision's primary focus is the acquisition, development and 
      marketing of compounds and technologies for the treatment of cancer. 
      Bioenvision has a broad pipeline of products for the treatment of 
      cancer, including: Evoltra®, 
      Modrenal® (for which 
      Bioenvision has obtained regulatory approval for marketing in the United 
      Kingdom for the treatment of post-menopausal breast cancer following 
      relapse to initial hormone therapy), and other products. Bioenvision is 
      also developing anti-infective technologies, including the OLIGON® 
      technology; an advanced biomaterial that has been incorporated into 
      various FDA approved medical devices and Suvus®, 
      an antimicrobial agent currently in clinical development for refractory 
      chronic hepatitis C infection. For more information on Bioenvision 
      please visit our Web site at www.bioenvision.com.
    
    
      Certain statements contained herein are "forward-looking" statements 
      (as such term is defined in the Private Securities Litigation Reform Act 
      of 1995). Because these statements include risks and uncertainties, 
      actual results may differ materially from those expressed or implied by 
      such forward-looking statements. Specifically, factors that could cause 
      actual results to differ materially from those expressed or implied by 
      such forward-looking statements include, but are not limited to: risks 
      associated with preclinical and clinical developments in the 
      biopharmaceutical industry in general and in Bioenvision's compounds 
      under development in particular; the potential failure of Bioenvision's 
      compounds under development to prove safe and effective for treatment of 
      disease; uncertainties inherent in the early stage of Bioenvision's 
      compounds under development; failure to successfully implement or 
      complete clinical trials; failure to receive marketing clearance from 
      regulatory agencies for our compounds under development; acquisitions, 
      divestitures, mergers, licenses or strategic initiatives that change 
      Bioenvision's business, structure or projections; the development of 
      competing products; uncertainties related to Bioenvision's dependence on 
      third parties and partners; and those risks described in Bioenvision's 
      filings with the SEC. Bioenvision disclaims any obligation to update 
      these forward-looking statements.